UroGen Pharma Ltd. (NASDAQ:URGN) Receives $43.70 Consensus Target Price from Analysts
Shares of UroGen Pharma Ltd. (NASDAQ:URGN – Get Free Report) have been assigned an average recommendation of “Buy” from the six research firms that are presently covering the stock, MarketBeat reports. Five equities research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The […]
Shares of UroGen Pharma Ltd. (NASDAQ:URGN – Get Free Report) have been assigned an average recommendation of “Buy” from the six research firms that are presently covering the stock, MarketBeat reports. Five equities research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The […]
